Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo ...

Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th at 10:30 a.m. PT/1:30 p.m. ET. Ahead of the presentation, Syndax ...

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

Choi Hyung-jin wins Im Seong-ki Researcher Award for obesity treatment breakthroughs Choi Hyung-jins groundbreaking ...

Mesoblast shares fall ~7% despite a $260 million placement following FDA approval for its cell therapy treatment ...

Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...